Biomarker Evaluation of Cannabinoids
Summary
We are looking for healthy adults to take part in a research study about the body’s natural system that helps control stress, anxiety, and mood. This system uses special chemicals called endocannabinoids, which can be measured in blood, saliva, and hair. The study has 6 visits and takes place at the Cal Wenzel Building at the Foothills Campus of the University of Calgary.
The first visit (Visit 1) will take about 45 minutes and includes questions about your health and lifestyle, measurements of height and weight, and collection of three blood and one hair sample. You will also receive saliva swabs to collect samples at home in the morning. Visits 2 to 6 will each take about 20 minutes and occur on days 1, 7, 14, 28, and 84. At every visit, you will give blood and answer questions about cannabis use, anxiety, and stress. A second hair sample will only be collected at Visit 6. You can schedule visits a few days before or after the planned dates, especially for later visits, to better fit your schedule.
Eligibility
Eligible ages: 18 to 60
Accepts healthy participants: Yes
Inclusion criteria:
In order to be eligible to participate in this study you must meet all the following criteria:
1. all sexes, gender identities, and ethnicities
2. between 18 and 60 years
3. ability to read/write English
4. willing to refrain from consuming cannabis, alcohol, nicotine and as-needed meds for at least 48h prior to each study visit and avoid engaging in strenuous physical activity on the day before the visit.
Exclusion criteria:
You are not eligible to participate in this study if you fulfill any of the following criteria:
1. current or history of psychiatric disorders (e.g. depression or addiction) which will be determined at the first session in a structured interview
2. diagnosis of endocrine disorder (e.g., Cushing’s syndrome)
Participate
Additional information
Contact information
BECKHAM-IV Study Team Psychedelics and Cannabinoid Therapeutics (PaCT) lab Marc D. Ferger, MD University of Calgary 1403 29 Street NW, Calgary, Alberta T2N 2T9
Principal investigator:
Leah Mayo
Clinical trial:
No
REB-ID:
REB25-1156